ロード中...

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis

Dalfampridine extended release (ER) 10 mg is an oral tablet form of the potassium (K(+)) channel-blocking compounded dalfampridine, also known as fampridine, and chemically 4-aminopyridine or 4-AP, which received regulatory approval in the United States for the treatment of walking in patients with...

詳細記述

保存先:
書誌詳細
第一著者: Hayes, Keith C
フォーマット: Artigo
言語:Inglês
出版事項: Dove Medical Press 2011
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3090287/
https://ncbi.nlm.nih.gov/pubmed/21573085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S10469
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!